Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced the Company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE